Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

Frederick L. Locke; David B. Miklos; Caron A. Jacobson; Miguel‐Angel Perales; Marie José Kersten; Olalekan O. Oluwole; Armin Ghobadi; Aaron P. Rapoport; Joseph P. McGuirk; John M. Pagel; Javier Muñoz; Umar Farooq; Tom van Meerten; Patrick M. Reagan; Anna Sureda; Ian W. Flinn; Peter Vandenberghe; Kevin Song; Michael Dickinson; Monique C. Minnema; Peter A. Riedell; Lori A. Leslie; Sridhar Chaganti; Yin Yang; Simone Filosto; Jina Shah; Marco Schupp; Christina To; Paul Cheng; Leo I. Gordon; Jason R. Westin

doi:10.1056/nejmoa2116133

Abstract

Axi-cel therapy led to significant improvements, as compared with standard care, in event-free survival and response, with the expected level of high-grade toxic effects. (Funded by Kite; ZUMA-7 ClinicalTrials.gov number, NCT03391466.).

Keywords

ChemoimmunotherapyMedicineHazard ratioClinical endpointInternal medicineOncologyTransplantationSurgeryLymphomaConfidence intervalClinical trialRituximab

Affiliated Institutions

Related Publications

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

Michael Wang , Javier Muñoz , André Goy +22 more

KTE-X19 induced durable remissions in a majority of patients with relapsed or refractory mantle-cell lymphoma. The therapy led to serious and life-threatening toxic effects that...

2020 New England Journal of Medicine 1666 citations

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

Nikhil C. Munshi , Larry D. Anderson , Nina Shah +25 more

Ide-cel induced responses in a majority of heavily pretreated patients with refractory and relapsed myeloma; MRD-negative status was achieved in 26% of treated patients. Almost ...

2021 New England Journal of Medicine 2137 citations

Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

Michael A. Postow , Jason Chesney , Anna C. Pavlick +18 more

The objective-response rate and the progression-free survival among patients with advanced melanoma who had not previously received treatment were significantly greater with niv...

2015 New England Journal of Medicine 2716 citations

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

Ian D. Davis , Andrew Martin , Martin R. Stockler +29 more

Enzalutamide was associated with significantly longer progression-free and overall survival than standard care in men with metastatic, hormone-sensitive prostate cancer receivin...

2019 New England Journal of Medicine 1481 citations

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Stephen J. Schuster , Michael Bishop , Constantine S. Tam +21 more

In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, high rates of durable responses were produced with the use o...

2018 New England Journal of Medicine 3775 citations

Publication Info

Year: 2021
Type: article
Volume: 386
Issue: 7
Pages: 640-654
Citations: 1322
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1322

OpenAlex

Cite This

APA Style

                            
                                
                                    Frederick L. Locke, 
                                
                                    David B. Miklos, 
                                
                                    Caron A. Jacobson
                                
                                et al.
                            
                            (2021). 
                            Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. 
                            New England Journal of Medicine
                            , 386
                            (7)
                            , 640-654.
                            https://doi.org/10.1056/nejmoa2116133
                        

Identifiers

DOI: 10.1056/nejmoa2116133